Subarachnoid Bupivacaine in Obese Patients Undergoing Cesarean Delivery

• Status: Completed
• Trial end date: 2018-05-30
• Target enrollment: 0
• Participant gender: Female

Summary

This study evaluates the effect of subarachnoid hyperbaric bupivacaine on mean arterial blood pressure (MAP) of pregnant patients with obesity undergoing cesarean section half of the patients will receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg while the other half will receive a dose of 10 mg

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Civil de Guadalajara
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Patients with single fetus pregnancy ≥37 weeks gestation

• Body mass index (BMI) ≥ 30 kg / m2

• Indication of termination of pregnancy via abdominal caesarean section

• Indication of subarachnoid neuraxial block under mixed technique

• Signing of consent under information

Exclusion Criteria:

• Patients with a known allergy to local anesthetics

• Patients with psychiatric treatment (antidepressants, anxiolytics, antipsychotics)

• Patients with addiction to any type of drug

• Patients with a history of liver disease

• Patients with a history of renal pathology

• Patients with a history of pulmonary pathology

• Patients with a history of cardiac pathology

• Patients with a history of high blood pressure

• Patient with a history of type I, II and gestational diabetes

• Non-calming fetal state

• Patients who refuse the anesthetic technique of neuraxial block